For instance, nilotinib belongs to therapeutic agents used in the clinic that inhibit the tyrosine kinase activity of the fusion oncogene BCR‐ABL and are highly effective against Chronic Myeloid Leukaemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.